OncoPharm

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

Delve into the fascinating origins of Acute Myelogenous Leukemia treatment with a look back at pivotal studies and key clinical trials. Discover the impactful evolution of the 7 plus 3 chemotherapy regimen that revolutionized AML therapy since the 1970s. The conversation also breezes through nostalgic references to 1975 films, weaving together a mix of historical insights and contemporary relevance in cancer treatment.

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.

Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/

This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0 Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187

We quickly cover some of the ASCO GI highlights from a couple weeks ago and delve deep into the role of ICIs in metastatic esophageal caner. Finally, does tebentafusp's approval tell us anything about the future intersection of immunotherapy and precision medicine?

Dr. Howard McLeod joins the pod to talk Precision Medicine and the role pharmacists can play using pharmacogenomics and tumor genomics in cancer care. https://www.drhowardmcleod.com

Topic covered include the latest updates to the seminal Hallmarks of Cancer work, adjuvant pembrolizumab for stage IIB/IIC melanoma, a prospective study of UGT1A1 testing, and Keynote-775. Hallmarks of Cancer: New Dimensions. https://cancerdiscovery.aacrjournals.org/content/12/1/31 UGT1A1 Genotype-guided dosing of irinotecan: https://doi.org/10.1016/j.ejca.2021.12.009 Keynote-775: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330

Dive into the world of carfilzomib, a key player in the fight against multiple myeloma. Discover its unique mechanism of action and how it stacks up against bortezomib. The discussion highlights important dosing strategies and potential side effects. Recent studies are also examined, aimed at improving patient outcomes and clinical practices. It's an insightful exploration of innovative treatments in oncology!

We're joined by Dr. Ryan McDade to hear about working as a Clinical Pharmacy Lead for Humana Specialty Pharmacy.